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BACKGROUND: Enzyme-linked immunoassays of full-length (M65) and/or caspase-cleaved (M30) cytokeratin 18 (CK18) released from
epithelial cells undergoing necrosis and/or apoptosis, respectively, may have prognostic or predictive biomarker utility in a range of
solid tumour types. Characterisation of baseline levels of circulating full length and cleaved CK18 specifically in patients with pancreatic
cancer.
METHODS: Plasma samples from 103 patients with pancreatic cancer stored at  801C were assayed for M65 and M30 levels. The
median (inter-quartile range (IQR)) duration of plasma storage was 34 (23–57) months. Patients with metastatic disease (n¼19)
were found to have greater median (IQR) M65 levels (1145 (739–1698)Ul
 1) compared with the locally advanced (n¼20; 748
(406–1150)Ul
 1) and resected (n¼64; 612 (331–987)Ul
 1) patients (P¼0.002). Elevated M65 levels were associated with
poorer overall survival on univariate (Po0.001) but not multivariate (P¼0.202) analysis. M65 concentrations also exhibited
significant associations with concurrent serum–bilirubin levels (Po0.001) and the duration of plasma storage (Po0.001).
CONCLUSIONS: Baseline plasma CK18 levels in pancreatic cancer are affected by the presence of obstructive jaundice and prolonged
plasma storage. Clinical biomarker studies utilising serial CK18 levels are warranted in pancreatic cancer, provided consideration is
given to these potentially confounding factors.
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Pancreatic ductal adenocarcinoma is a leading cause of cancer
deaths (http://www-dep.iarc.fr/) wherein, because of its character-
istically late presentation, only 10–15% of patients present with
resectable tumours (Alexakis et al, 2004). For the remaining
85–90% of patients presenting with inoperable disease, adminis-
tration of systemic chemotherapy represents the most widely
utilised palliative treatment modality (Yip et al, 2006). Conven-
tional chemotherapy regimens incorporating either 5-FU or
gemcitabine typically result in only modest improvement in
overall survival (Sultana et al, 2007). One of the key challenges
in accelerating improved cancer therapeutics is the identification
of biomarkers to enable early objective assessment of tumour
responses to chemotherapy (Kummar et al, 2007).
Necrosis of malignant and normal epithelial cells cause release
of cytokeratin 18 (CK18) (Kramer et al, 2004), a type I intermediate
filament protein and a component of the intracellular cytoskeleton
(Fuchs and Weber, 1994). Caspase-mediated cleavage of the CK18
contributes to the degradation of the intracellular cytoskeleton if
epithelial cells undergo apoptosis (Leers et al, 1999). Enzyme-
linked immunosorbent assays (ELISAs) have been developed to
measure circulating concentrations of both full-length CK18 (M65)
and caspase-cleaved CK18 fragments (M30) (Kramer et al, 2004).
Thus, the M65 ELISA reports necrotic and apoptotic epithelial cell
death, whereas the M30 ELISA reports levels of epithelial apoptosis
specifically (Kramer et al, 2004). Early studies suggest that these
assays may have important clinical biomarker utility, as increased
levels of circulating CK18 may be prognostic and/or predict
tumour response to chemotherapy in a number of different solid
tumours (Steele et al, 2008; Scott et al, 2009). Studies on specific
tumour types include lung (Ulukaya et al, 2007; Hou et al, 2009),
breast (Olofsson et al, 2007), prostate (Kramer et al, 2006), head
and neck (Ozturk et al, 2009), colorectal (Ausch et al, 2009;
Koelink et al, 2009) and testicular (de Haas et al, 2008) tumours.
Although a recent study concluded that plasma levels of CK18 are a
potential marker of tumour response in patients with advanced
gastrointestinal malignancy (Scott et al, 2009) no previous studies
have been reported in patients with pancreatic cancer.
The objective of this study was to characterise the baseline levels
of circulating plasma CK18 concentrations using both the M65 and
M30 ELISA assays in patients with pancreatic cancer. Correlations
were also examined between CK18 and the circulating levels
of carbohydrate antigen 19-9 (CA19-9), the only widely used
biomarker in pancreatic cancer (Smith et al, 2008). Preoperative
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sbiliary stenting and concurrent liver function were also investi-
gated in the interpretation of CK18 levels, as obstructive jaundice
has been shown to be a confounding factor in proteomic studies
(Yan et al, 2009) along with effect of plasma storage duration
(Cummings et al, 2007; Greystoke et al, 2008).
MATERIALS AND METHODS
Patients and plasma collection
A total of 103 non-consecutive pancreatic adenocarcinoma
patients with stored samples, treated at the Royal Liverpool
University Hospital between 1997 and 2007 were identified from a
prospective clinical database. All patients gave written consent for
blood, tissue and clinical data to be used for research purposes.
All patients with obstructive jaundice routinely underwent
biliary stenting at endoscopic retrograde cholangio-pancreato-
graphy. If endoscopic biliary decompression was unsuccessful,
patients underwent percutaneous transhepatic cholangiography or
combined procedures in order to decompress the biliary tree. In
all, 64 patients then underwent a surgical resection for histologi-
cally confirmed pancreatic ductal adenocarcinoma (35 men and
29 women) with a median age of 68 (inter-quartile range
(IQR)¼61–73) years. A total of 39 patients had advanced
pancreatic adenocarcinoma (22 men and 17 women) with a
median age of 68 (IQR¼58–77) years. The diagnosis of advanced
disease was made at laparotomy in 30 of 39 (77%) patients. The
remaining 9 cases (26%) were diagnosed as unresectable on initial
imaging or at staging laparoscopy. In all, 15 of 64 patients
undergoing resection went on to receive adjuvant therapy,
chemotherapy in 13 and chemoradiotherapy in two. Patients with
advanced cancer were managed at multiple referral institutions
and data relating to palliative chemotherapy were available for 22
patients, 8 of whom had undergone chemotherapy. There was no
significant change of the adjuvant or palliative therapy protocols
during the study period.
Plasma was collected on the day before surgical intervention and
stored at  801C. Plasma was collected at the time of diagnosis in
the nine patients managed nonoperatively. The median time
interval for plasma storage (from the date of plasma collection to
the date of assay) was 34.1 (IQR¼22.7–57.0) months. Preopera-
tive serum CA19-9 and concurrent bilirubin levels were also
retrieved, along with details regarding resected histopathological
tumour characteristics and patient survival data. Overall survival
times were calculated from the date of plasma sampling to the date
of death.
Detection of M65 and M30 antigens
The M65 and M30 (Apoptosense) ELISA kits (Peviva, Stro ¨skarls-
va ¨gen, Sweden) were used for the plasma biomarker analyses
according to previously described methods and according to good
clinical laboratory practice (GCLP, Cummings et al, 2005). An
apoptotic index was calculated from the ratio of caspase-cleaved
CK18 as a proportion of overall CK18 (M30 divided by M65) as
previously described (Kramer et al, 2004).
Preparation of tissue microarray (TMA)
The original haematoxylin and eosin (H&E) stained histopathology
slides from resected cases were retrieved and reviewed by a
consultant pathologist (FC). Slides were marked in order to target
cancer cores for subsequent sampling from stored paraffin-
embedded tissue blocks. It was ensured that targeted areas were
away from resection margins to avoid diathermied tissue.
Duplicate cores taken from three areas within each tissue block
were sampled for each patient. Normal tissue from kidney, colon
and duodenum were used for orientation cores. Five control blocks
from chronic pancreatitis specimens were also used in the TMA.
The marked slide and paraffin-embedded tissue block were
aligned so that the targeted area of tumour on the donor block
could be determined. Using a manual tissue arrayer (Beecher
Instruments, Sun Prairie, WI, USA), 0.6mm diameter tissue cores
were taken to a depth of 4mm from the targeted area of tumour in
the donor block. The tissue cores were placed into the recipient
paraffin block 1mm apart. The TMA blocks were cut using a Leica
Reichert-Jung BIOCUT 2035 microtome (Leica Biosystems,
Wetzlar, Germany) in 5mm sections. Two 5mm sections were cut
Figure 1 (A) Example of shed cells within a cancer gland exhibiting
positive staining for activated caspase-3 on immunohistochemistry
(arrowed) in a core of pancreatic ductal adenocarcinoma. (B) Example
of sporadic nature of activated caspase-3 staining within the malignant
ductal epithelium. (C) Haematoxylin and eosin (H&E) stained slide of
pancreatic ductal adenocarcinoma exhibiting widespread tumour necrosis.
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sfrom each block and mounted on X-tra adhesive Surgipath slides
in preparation for immunohistochemistry (IHC).
Detection of cleaved caspase 3
Cleaved caspase 3 was assessed by immunohistochemistry using a
validated method to GCLP. Tissue microarray sections were
deparaffinised, re-dehydrated and antigen retrieval was carried
out using microwaves for 25min in citric acid buffer (10mM,p H
6.0). Sections were then blocked by immersing in a 0.3% hydrogen
peroxide solution for 30min to remove exogenous and endogenous
peroxidase. The slides were blocked using 10% casein solution
for 1h to remove background staining. Slides were then incubated
overnight with the primary antibody (Cell Signaling Technology,
Boston, MA, USA; ref: #9661S) at 41C in a humidified tray. Slides
were then washed in PBS and goat anti-rabbit (Vectastain ABC kit
from Vector Laboratories, Burlingame, CA, USA; ref: PK-4001)
secondary antibody was added for 30min. The slides were washed
with PBS and ABC kit (Envision kit, Vector Laboratories) was
applied (according to manufacturer’s instructions). Sections were
washed in PBS before visualization of signal using DAB reagent.
Sections were then counterstained with haematoxylin before
mounting.
Immunohistochemical scoring
The activated caspase-3 immunohistochemistry was scored by a
consultant pathologist (FC) according to the presence of positive
staining in the intraluminal shed cells within cancer glands
(Figure 1A). Only tissue cores exhibiting one or more shed cells
were scored. Cases were classified as either positive or negative
based on the proportion of positively stained cells present. Cases
where more than 50% of shed cells exhibited positive staining in a
majority of cancer cores were classified as positive. Owing to the
infrequent staining exhibited in the intact malignant epithelium
(Figure 1B), no attempt to score the epithelial staining was made.
The original H&E stained histopathology slides for the resected
pancreatic specimens were also evaluated by the same consultant
pathologist (FC) to make a quantitative assessment of tumour
necrosis on microscopic examination. Cases were allocated a
percentage score (0, 1, 5, 10, 25 or 50%) according to the
proportional area of tumour material exhibiting microscopic features
of necrosis (Figure 1C). Areas of fibrosis, sclerosis and autolysis on
microscopy were not included as part of this assessment. The
pathologist was blinded to the ELISA results and survival data during
scoring of both the activated caspase-3 immunohistochemistry and
the microscopic assessment of tumour necrosis.
Statistical analysis
Continuous data were described using median values, IQR and
95% confidence intervals (CIs) with Mann–Whitney U-testing or
Kruskal–Wallis testing for non-parametric comparisons of
continuous data. Categorical data were analyzed using the w
2 test.
Spearman’s rank correlation was used to analyse the relationship
between two individual continuous variables. CA19-9 was normal-
ised for regression analyses by logarithmic transformation
(logeCA19-9). Survival data were analysed using the Kaplan–
Meier method with log-rank testing for the comparison of survival
curves. Cox’s proportional hazards regression was used for
multivariate analysis. Prognostic variables of univariate signifi-
cance were selected for inclusion in the multivariate model. A
P-value of 0.05 was considered significant.
RESULTS
Of the 103 patients analysed, plasma M65 levels were measureable
for 102 and M30 levels measureable for 98 patients. Both assays
were measureable for 97 patients. Table 1 gives details of the
demographic and clinicopathological data for the overall patient
group. The median (IQR) plasma M65 level recorded in the overall
patient group was 724 (411, 1188)Ul
 1, whereas the median
plasma M30 level was 212 (149, 327)Ul
 1 and the M30:M65 ratio
was 0.32 (0.24, 0.49). The median (IQR) reference values for M30
and M65 were determined in 82 healthy controls (30 men and
52 women) with a median age of 45 (35, 55) years and were 198
Table 1 Demographics and clinicopathological data
Total number of patients 103
Median age (IQR) (years) 68 (60–74)
Male:Female 57:46
Resected cases: 64
Median tumour size (IQR) (mm) 30 (22–38)
T1/T2:T3/T4 11:52
N0:N1 10:52
Well/moderate/poor differentiation 10/35/18
R0:R1 19:45
Unresected cases: 39
Locally advanced 20
Metastatic 19
Median M65 (IQR) (Ul
 1) 724 (411–1188)
Median M30 (IQR) (Ul
 1) 212 (149–327)
Median M30:M65 ratio (IQR) 0.32 (0.24–0.49)
Median preoperative CA19-9 (IQR) (kUl
 1) 463 (151–1265)
Median preoperative bilirubin (IQR) (mmoll
 1) 23 (12–57)
Median duration of plasma storage (IQR) (months) 34 (23–57)
CA¼carbohydrate antigen; IQR¼interquartile range. The median (IQR) time
interval from the date of preoperative CA19-9 estimation to the date of plasma
sampling was 28 (19, 38) days. The median (IQR) time interval for liver function tests
was 1 (1, 2) day. Histological data was incomplete for one patient. Preoperative
CA19-9 and bilirubin data were incomplete for 11 and 14 patients, respectively.
The median (IQR) values for M30 and M65 in 82 healthy controls were 198
(155, 317)Ul
 1 and 240 (191, 339)Ul
 1, respectively (Greystoke et al, 2008).
Table 2 Parameters according to resectability and presence of metastases
Resected cases
(N¼64)
Locally advanced
unresected cases (N¼20)
Metastatic unresected
cases (N¼19) P-value
Median age (IQR) (years) 68 (61–73) 70 (64–77) 65 (57–75) 0.406
Male:Female 35:29 8:12 14:5 0.105*
Median M65 (IQR) (Ul
 1) 611 (331–987) 748 (406–1150) 1145 (739–1698) 0.002
Median M30 (IQR) (Ul
 1) 192 (147–311) 215 (142–348) 324 (224–453) 0.058
Median M30:M65 ratio (IQR) 0.39 (0.24–0.50) 0.29 (0.21–0.40) 0.28 (0.25–0.33) 0.184
Median preoperative CA19-9 (IQR) (kUl
 1) 356 (81–893) 416 (217–2310) 1628 (581–3312) 0.007
Median preoperative bilirubin (IQR) (mmoll
 1) 22 (12–37) 23 (11–51) 99 (21–204) 0.004
Median duration of plasma storage (IQR) (months) 29 (21–42) 43 (29–60) 106 (32–114) 0.003
CA¼carbohydrate antigen; IQR¼inter quartile range. Quoted P-values for Kruskal–Wallis test. *w
2 P-value.
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s(155, 317)Ul
 1 and 240 (191, 339)Ul
 1, respectively (Greystoke
et al, 2008). The three clinical groups of resected, locally advanced
not resected and metastasis groups may be considered as
demonstrating increasing tumour burden and so the results for
the M30 and M65 levels and the M30:M65 ratios are shown by
these groups in Table 2. The median (IQR) M65 levels significantly
increased with increasing degrees of tumour burden being 1145
(572, 1479)Ul
 1 for patients with metastatic disease compared
with 748 (406, 1150)Ul
 1 in patients with locally advanced non-
resectable disease and 612 (331, 987)Ul
 1 in patients who had
resection (Kruskal–Wallis, P¼0.002; Table 2 and Figure 2).
Confounding factors
Carbohydrate antigen 19-9 (P¼0.007) and bilirubin (P¼0.004)
levels were also associated with the increasing tumour burden
(Table 2). Plasma M65 levels were found to exhibit a strong
correlation with concurrent serum–bilirubin levels (Spearman,
r¼0.439, Po0.001) but not CA19-9 levels. A significant correla-
tion between M65 levels and the duration of plasma storage overall
was found (Spearman, r¼0.487, Po0.001) and the period of
plasma storage was also unexpectedly found to be significantly
longer in the group with metastases (P¼0.007).
Plasma CK18 levels and survival
Resectability, the presence of metastases and M65, Ca19-9 and
bilirubin levels were all significantly associated with survival (all
Po0.001) on univariate analyses (Table 3 and Figure 3). Resected
patients had a median survival of 13.9 (95% CI¼11.0–16.4)
months compared with 7.3 (95% CI¼5.5–11.0) months for locally
advanced tumours and 2.5 (95% CI¼1.2–3.6) months for patients
with metastatic disease (log rank, Po0.001). Increasingly elevated
plasma M65 levels were associated with poorer survival in the
overall patient group on univariate analysis both as a continuous
(Cox, Po0.001; Table 3) and dichotomised variable (log rank,
P¼0.007; Figure 3B). Neither M30 levels (Cox, P¼0.052) nor the
M30:M65 ratio (Cox, P¼0.096) were significant univariate
prognostic variables in the overall patient group. The results of a
multivariate analysis including M65 levels, tumour resectability,
CA19-9 and bilirubin are shown in Table 3. In this model the only
independent significant prognostic factors were resectability and
the presence of metastases (both Po0.001).
Histopathological assessment of necrosis and apoptosis in
resected cases
There was no significant relationship between plasma CK18 levels
and tumour histology. The original histopathology slides with
corresponding paraffin-embedded tumour material were available
in 58 of 64 resected patients (91%). A total of 17 patients (29%)
exhibited significant areas of tumour necrosis (i.e. X5%) on
microscopic assessment. There was no significant correlation
between plasma M65 levels and the histological percentage score
for microscopic tumour necrosis (Spearman, r¼0.084, P¼0.531).
After the preparation of TMA, a total of 53 out of 58 cases had one
or more evaluable cores containing cancer. In all, 45 cases
exhibited shed cells, which could be evaluated for activated
caspase-3 staining. Of these 45 cases, 25 (56%) had positive
staining and 20 (44%) were negative. There was no significant
difference in the median plasma M30:M65 ratio between positive
(0.37 (IQR¼0.26–0.53)) and negative cases (0.36 (IQR¼0.26–
0.48)) for activated caspase-3 immunostaining (Mann–Whitney,
P¼0.478).
DISCUSSION
Cytokeratin 18 is a type I intermediate filament protein component
of the intracellular cytoskeleton in epithelial cells (Fuchs and
Kruskal-Wallis
P = 0.002
P
l
a
s
m
a
 
M
6
5
 
l
e
v
e
l
s
 
(
U
/
I
)
Resected
n=64
Locally advanced
n=20
Metastases
n=19
4000
3500
3000
2500
2000
1500
1000
500
0
Figure 2 Box plot illustrating the effect of tumour resectability and
presence of metastasis on plasma M65 levels. The dotted lines represent
the inter quartile range (IQR) reference values of 191 and 339Ul
 1 for
healthy controls (Greystoke et al, 2008).
Table 3 Survival analysis
Univariate analysis Multivariate analysis (n¼82)
Hazard ratio (95% CI) v
2 P Hazard ratio (95% CI) v
2 P
Tumour resectability: — 50.85 o0.001 24.73 o0.001
Resected (n¼64) — — — — — —
Locally advanced (n¼20) 2.742 (1.567–4.796) 12.50 o0.001 2.579 (1.340–4.962) 8.05 0.005
Metastases (n¼19) 8.489 (4.678–15.405) 49.50 o0.001 6.533 (3.048–14.000) 23.29 o0.001
Plasma M65 1.001 (1.000–1.001) 15.55 o0.001 1.000 (1.000–1.001) 1.63 0.202
LogCA19-9 1.235 (1.095–1.394) 11.72 o0.001 1.130 (0.964–1.325) 2.26 0.133
Bilirubin 1.003 (1.001–1.005) 11.01 o0.001 0.999 (0.995–1.003) 0.44 0.507
Chemotherapy 0.864 (0.505–1.476) 0.29 0.592 — — —
CA¼carbohydrate antigen; CI¼confidence interval. *Plasma M65 levels, CA19-9 and bilirubin were modelled as continuous prognostic covariates. Quoted hazard ratios for
continuous variables signify the relative hazard associated with each incremental increase in the covariate value by 1 U. Logarithmic transformation of CA19-9 results was
undertaken to normalise for Cox’s regression because of the wide range of preoperative CA19-9 results recorded in the overall patient group (from 1–90000kUl
 1).
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sWeber, 1994). Increasing evidence exists to suggest that cyto-
keratins have an important role during epithelial apoptosis.
Degradation of type I cytokeratins (including CK18) by activated
caspases 3, 7 and 9 with consequent loss of mechanical integrity of
the cell occurs during the execution phase of apoptosis to facilitate
cell shrinkage and formation of apoptotic bodies (Leers et al, 1999;
Schutte et al, 2004). During this process, CK18 is cleaved at two
specific sites along the non-helical linker region of the protein
(Asp238 and Asp396) exposing the Asp396 neo-epitope with
the subsequent release of cleaved cytokeratin fragments into the
extracellular space. Detection of this Asp396 neo-epitope by the
M30 ELISA is, therefore, only possible following caspase-
dependent apoptosis. It has been postulated that necrosis of
epithelial cells releases full-length cytokeratins into the extra-
cellular space following breakdown of the cell membrane
(Bodenmu ¨ller et al, 1994). In vitro studies have shown that
induction of necrosis in a human breast epithelial cell line is
associated with a significant increase in the concentration of
extracellular CK18, as recorded by the M65 ELISA (Kramer et al,
2004).
This study represents the first attempt to characterise circulating
levels of CK18 in patients with pancreatic cancer in order to assess
its clinical biomarker potential. The results from the M30 and M65
ELISA assays showed significant variability between patients with
regard to the baseline levels of both full-length CK18 (M65) and the
proportion of caspase-cleaved CK18 (M30:M65). Circulating total
CK18 concentrations in this study were relatively high compared
with prostate (Kramer et al, 2006) and breast (Olofsson et al, 2007)
cancer and comparable with those of other gastrointestinal
malignancies (Scott et al, 2009) and non-small-cell lung cancer
(Hou et al, 2009). In keeping with the other malignant tumour
types (Ulukaya et al, 2007; Hou et al, 2009; Koelink et al, 2009),
elevated CK18 levels were associated with poorer survival in the
overall patient group on univariate analysis, but in this series failed
to reach significance on multivariate analysis.
There was no significant association between plasma M65 levels
and the histopathological assessment of tumour necrosis. This
finding may implicate additional factors other than intrinsic
tumour biology having an important confounding effect on
circulating M65 concentrations. A marked correlation was seen
between the concurrent bilirubin levels and circulating CK18
levels. This observation is likely to be explained on the basis that
obstruction of the main bile duct with consequent dilatation and
epithelial disruption directly influences the balance of proliferation
and cell death within the biliary epithelium (Lesage et al, 2001;
Alpini et al, 2003). Low-grade cholangitis is quite common
following biliary stenting and may also represent an additional
confounding factor, as both generalised sepsis (Roth et al, 2004)
and cholangitis (Yagmur et al, 2007) raise circulating CK18
concentrations. Other studies have demonstrated significant
disturbances in circulating CK18 in patients with chronic liver
disease (Hetz et al, 2007; Yagmur et al, 2007).
Information on the long-term antigen stability of the M30 and
M65 ELISAs in stored human plasma is limited. A previous study
(Cummings et al, 2007) in 20 patients with cancer showed no
significant degradation of the M65 antigen after 2 years of storage
at  80
oC although the M30 antigen exhibited increased values with
extended storage in a proportion of patients and confirmed in a
more recent study (Greystoke et al, 2008). The results from this,
much larger, study have shown that antigen levels exhibit a trend
towards more elevated values when stored over a longer period.
Appropriate pre-clinical validation of potential cancer bio-
markers is essential before their utilisation in either routine
clinical practice or trial settings (Cummings et al, 2008). This study
highlights the fact that the pathophysiology of pancreatic cancer
presents a number of different challenges with regard to the
analysis of blood–borne biomarkers. Studies utilising serial CK18
measurements to determine tumour responses to cytotoxic therapy
in pancreatic cancer should give adequate consideration to the
potential confounding factors of concurrent obstructive jaundice
and the duration of sample storage.
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Figure 3 Kaplan–Meier curves to illustrate survival trends in overall
patient group. (A) The expected pattern of worsening survival associated
with more advanced disease was observed. The survival curves according
to plasma M65 levels (B) were comparable with those seen for serum
carbohydrate antigen (CA)19-9 levels (C) in the overall patient group.
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